PRESS RELEASE published on 06/19/2025 at 17:46, 7 months 10 days ago Inside Information / Other news releases Poxel presents new Imeglimin data at ADA 2025 diabetes conference, highlighting therapeutic potential. Key presentations by Japanese experts Diabetes Therapeutic Potential Poxel Imeglimin ADA 2025
BRIEF published on 06/06/2025 at 19:10, 7 months 23 days ago Poxel: Details of share capital and voting rights Share Capital Voting Rights Actions Regulated Information Poxel
BRIEF published on 05/28/2025 at 07:35, 8 months 2 days ago TWYMEEG® Data Unveiled at Japan Diabetes Society Meeting Clinical Trials Diabetes Treatment TWYMEEG® Poxel SA Japan Diabetes Society
PRESS RELEASE published on 05/28/2025 at 07:30, 8 months 2 days ago Inside Information / Other news releases New clinical and scientific data on TWYMEEG® to be presented at the 68th Annual Meeting of the Japan Diabetes Society, showcasing efficacy, safety, and benefits in diverse patient groups Clinical Data Scientific Data TWYMEEG® Sumitomo Pharma Japan Diabetes Society
BRIEF published on 05/13/2025 at 07:35, 8 months 17 days ago Poxel's First Quarter 2025 Revenue and Business Developments Regulatory Approval Corporate Strategy Poxel Revenue TWYMEEG® Sales Royalties Increase
PRESS RELEASE published on 05/13/2025 at 07:30, 8 months 17 days ago Inside Information / Information on annual revenues Poxel reports consolidated revenue and corporate updates for Q1 2025, with TWYMEEG® sales growth in Japan and regulatory approval for diabetic patients with renal impairment Revenue Regulatory Approval Japan Poxel TWYMEEG
BRIEF published on 03/20/2025 at 21:50, 10 months 9 days ago Poxel Releases Positive Preclinical Results for HCM Treatment Preclinical Study Hypertrophic Cardiomyopathy PXL065 Myocardial Remodeling Cardiac Fibrosis
PRESS RELEASE published on 03/20/2025 at 21:45, 10 months 9 days ago Inside Information / Other news releases Poxel announces positive preclinical study results for PXL065, a potential treatment for Hypertrophic Cardiomyopathy, showing benefits in a mouse model Preclinical Study Poxel Hypertrophic Cardiomyopathy PXL065 Mouse Model
BRIEF published on 02/11/2025 at 20:33, 11 months 18 days ago Poxel Holds Combined General Meeting, Announces Key Results General Meeting Shareholder Voting Financial Delegations Remuneration Policy Poxel SA
PRESS RELEASE published on 02/11/2025 at 20:28, 11 months 18 days ago Inside Information / Other news releases Poxel announces results of its Combined General Meeting with approved resolutions on revised remuneration policy for corporate officers. Details available on company's website Voting Results Financial Press Release Combined General Meeting Poxel Remuneration Policy
Published on 01/30/2026 at 14:00, 2 hours 15 minutes ago CCL to Hold Live Webcast to Discuss Fourth Quarter and Year End 2025 Results, Thursday, February 26, 2026, at 7:30 a.m. ET
Published on 01/30/2026 at 08:35, 7 hours 40 minutes ago Alaska Energy Metals Announces Closing Of Life Offering of Units
Published on 01/30/2026 at 08:00, 8 hours 15 minutes ago Troubadour Resources Intercepts Target Mineralization Near Surface during Phase 1 of the Multi-Phase Drill Program at Senneville Gold-Silver-Copper Property
Published on 01/30/2026 at 02:15, 14 hours ago Canex Metals Announces Success of Gold Basin Take-Over Bid, Extension of the Partial Revocation of the Cease-Trade Order Imposed on Gold Basin, Waiver of All Remaining Conditions, Initiation of the Share Take Up Process, and Mandatory 10-Day Extension
Published on 01/30/2026 at 00:00, 16 hours 15 minutes ago LIR Life Sciences Reports Positive Interim Preclinical Results from Comparative Animal Study of Novel CPP-Enabled Transdermal Delivery of GLP/GIP-Based Therapies
Published on 01/30/2026 at 16:00, 15 minutes ago Form 8.3 - The Vanguard Group, Inc.: Dauch Corporation
Published on 01/30/2026 at 15:57, 17 minutes ago Form 8.3 - The Vanguard Group, Inc.: Avadel Pharmaceuticals plc
Published on 01/29/2026 at 18:00, 22 hours 15 minutes ago GUILLEMOT CORPORATION: FULL-YEAR 2025 CONSOLIDATED TURNOVER UP 2%
Published on 01/29/2026 at 17:45, 22 hours 30 minutes ago LANSON-BCC ANNOUNCES 2025 REVENUES AND FINALISES THE ACQUISITION OF HEIDSIECK & C° MONOPOLE
Published on 01/29/2026 at 17:45, 22 hours 30 minutes ago Cegedim generated LFL revenue growth of 1.1% in 2025
